Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $11.79

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $11.79.

A number of equities analysts have commented on HCAT shares. JPMorgan Chase & Co. boosted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Wednesday, September 4th. Royal Bank of Canada boosted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Piper Sandler reaffirmed an "overweight" rating and set a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Stephens boosted their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Thursday, November 14th. Finally, Citigroup upped their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the company a "buy" rating in a report on Wednesday, November 13th.

Health Catalyst Stock Up 1.7 %

Shares of Health Catalyst stock traded up $0.12 during trading on Friday, hitting $7.09. 937,597 shares of the stock traded hands, compared to its average volume of 563,835. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock's fifty day simple moving average is $8.13 and its 200 day simple moving average is $7.45. The firm has a market cap of $431.41 million, a P/E ratio of -5.25 and a beta of 1.31. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. During the same period last year, the business posted ($0.22) EPS. The company's revenue for the quarter was up 3.5% on a year-over-year basis. On average, equities analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the transaction, the chief operating officer now owns 134,899 shares of the company's stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jason Alger sold 19,599 shares of the firm's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now directly owns 86,712 shares in the company, valued at approximately $721,443.84. This trade represents a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,551 shares of company stock worth $532,105. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Health Catalyst during the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC lifted its holdings in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock valued at $41,000 after purchasing an additional 5,232 shares in the last quarter. Quarry LP grew its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock valued at $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the third quarter worth about $59,000. Finally, Mackenzie Financial Corp acquired a new position in shares of Health Catalyst during the 2nd quarter worth about $70,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.